Hikal Limited · NSE:HIKAL
Hikal — Q4 FY2021 Earnings Presentation
26 slides from Hikal's earnings presentation, May 7, 2021
Slide 1: Cover letter to stock exchanges
May 7, 2021 Dept. of Corporate Services, Listing Department, BSE Ltd., National Stock Exchange of India Ltd., P J Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai - 400 001. Mumbai 400051. BSE Scrip Code: 524735 NSE Symbol : HIKAL Dear Sir/ Madam, Subject: Results Pr
Slide 2: Results Presentation – Q4 & FY 2020-21
Results Presentation – Q4 & FY 2020-21
Slide 3: Safe Harbor
Safe Harbor H fy K. A xk This presentation and the accompan ing slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any se
Slide 4: CMD's Message
CMD’s Message “I am happy to report that we have achieved a record performance for Q4 as well as for the full financial year. Despite the disruption in H1 on account of the Covid-19 pandemic, we have substantially recovered during H2. On an annual basis, we registered a revenue growth of 14% whereas
Slide 5: Quarterly Financials Highlights
Quarterly Financials Highlights
Slide 6: Revenue – Q4FY21 Rs. 532 Crore
Positive momentum from Q3 continued in Q4 to continue a strong growth trajectory Revenue – Q4FY21 EBITDA – Q4FY21 EBITDA Margin – Q4FY21 Rs. 532 Crore Rs. 109 Crore 20.5% QoQ YoY QoQ YoY QoQ YoY 15% 40% 20% 55% 81 Bps 188 Bps PAT – Q4FY21 EPS – Q4FY21 Rs. 51 Crore Rs 4.13 QoQ YoY QoQ YoY 26% 108% 26
Slide 7: Quarterly Performance Highlights
Quarterly Performance Highlights Revenue +40% 532 Operational Performance Highlights 463 +15% 379 • Revenue recorded an increase of 40% YoY and 15% QoQ • First ever quarter with revenue in excess of Rs. 500 Crore • Better sales volumes of key existing products Q4FY20 Q3FY21 Q4FY21 • Strong performan
Slide 8: Quarterly Performance Highlights – Pharmaceutical
Quarterly Performance Highlights – Pharmaceutical Revenue +32% Pharmaceutical - Performance Highlights 298 269 +11% • Revenue recorded an increase of 32% YoY and 11% QoQ 226 • Strong growth in volumes of own and CDMO products • EBIT increased to Rs. 51 Crore, growth of 53% YoY and 6% QoQ • Business
Slide 9: Quarterly Performance Highlights – Crop Protection
Quarterly Performance Highlights – Crop Protection Revenue +54% Crop Protection - Performance Highlights 235 +21% • Revenue recorded an increase of 54% YoY and 21% QoQ 194 • Orders deferred in H1 due to pandemic were executed in H2 153 • New capacities have come on stream through the capex incurred
Slide 10: Quarterly Operational Highlights
Quarterly Operational Highlights +40% +55% +108% 532 109 51 463 +15% +20% 91 +26% 40 379 372 353 71 70 27 53 24 15 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 © Hikal Limited
Slide 11: Quarterly Operational Highlights
Quarterly Operational Highlights +32% +54% 298 279 269 235 +11% 226 214 194 +21% 153 139 93 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 +53% +72% 50 51 48 48 +6% +55% 33 31 28 22 17 8 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 © Hikal Limited
Slide 12: Annual Financials Highlights
Annual Financials Highlights
Slide 13: Operational Highlights - Annual
Operational Highlights - Annual Revenue – FY21 EBITDA – FY21 EBITDA Margin – FY21 Rs. 1,720 Crore Rs. 323 Crore 18.8% FY17-21 FY17-21 YoY YoY YoY CAGR CAGR 14% 18% 65 Bps 14% 13% PAT – FY21 EPS – FY21 Rs. 133 Crore Rs 10.80 FY17-21 FY17-21 YoY YoY CAGR CAGR 58% 58% 19% 19% © Hikal Limited
Slide 14: Annual Performance Highlights
Annual Performance Highlights Revenue Operational Performance Highlights +14% • Revenue increased by 14% YoY to reach Rs. 1,720 Crore 1,507 1,720 • Higher volumes of key products • Strong performance in newly commercialized CDMO as well as own products • Penetration in new markets FY20 FY21 • EBITDA
Slide 15: Annual Performance Highlights – Pharmaceutical Division
Annual Performance Highlights – Pharmaceutical Division Revenue +19% Pharmaceutical - Performance Highlights 1,060 887 • Revenue recorded an increase of 19% YoY • Robust growth in key Generics and CDMO products • Successful scale-up and growth of new products in CNS and anti-depressant therapy areas
Slide 16: Annual Performance Highlights – Crop Protection Division
Annual Performance Highlights – Crop Protection Division Revenue +7% Crop Protection - Performance Highlights 661 620 • Revenue recorded an increase of 7% YoY • Strong recovery in H2 after a challenging H1 • We expect this strong momentum to continue in FY 2021-22 • EBIT increased to Rs. 103 Crore,
Slide 17: Yearly Operational Highlights
Yearly Operational Highlights +14% +13% 1,720 323 133 1,590 298 1,507 +19% 273 1,300 242 103 197 84 1,034 77 67 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 © Hikal Limited
Slide 18: Yearly Operational Highlights
Yearly Operational Highlights +12% +15% 1,060 651 661 620 939 887 547 753 423 611 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 +8% +21% 170 112 100 103 129 128 87 75 99 79 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 © Hikal Limited
Slide 19: Segmental Break-Up
Segmental Break-Up CDMO CDMO Own products Own products 41.2% 54.0% 69.0% 76.7% 58.8% 46.0% 31.0% 23.3% FY20 FY21 FY20 FY21 © Hikal Limited
Slide 20: Consolidated Profit & Loss – Quarter & Full Year
Consolidated Profit & Loss – Quarter & Full Year © Hikal Limited
Slide 21: Consolidated Balance Sheet
Consolidated Balance Sheet © Hikal Limited
Slide 22: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Adjustments 127 136 Change in operating assets and liabilities (58) 46 Income taxes paid Exceptional Item* © Hikal Limited
Slide 23: Ratio Analysis
Ratio Analysis ROE ROCE Return Ratio • We have seen a rise in our return ratios of ROE and ROCE for FY21 after a dip in the last year • We expect our ratios to consistently show the same progress to reach the best-in-class profile Net Debt/Equity • We have been able to reduce our Net Debt/Equity rat
Slide 24: Annual Dividend Payout
Annual Dividend Payout 21% 19% 14% 24% 22% 18% 19% 17% 20% 19% 10.80 EPS DPS 8.36 6.85 6.27 5.70 5.18 4.39 3.28 3.35 2.05 2.00 1.20 1.00 1.00 1.20 1.20 1.20 1.20 0.90 0.50 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 ▪ © Hikal Limited
Slide 25: Contact Us
Contact Us HIKAL Company : Hikal Limited CIN: L24200MH1988PTC048028 Mr Kuldeep Jain Kuldeep _jain@hikal.com www.hikal.com HiKAL SG A Strategic Growth Advisors Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285 Mr. Jigar Kavaiya +91-9920602034 jigar.kavaiya@sg
Slide 26: HIKAL
HIKAL